Point-Counterpoint: Active Surveillance for Intermediate-Risk Prostate Cancer - Con

preview_player
Показать описание

  1. Grand Rounds in Urology
Рекомендации по теме
Point-Counterpoint: Active Surveillance 0:09:15

Point-Counterpoint: Active Surveillance for Intermediate-Risk Prostate Cancer - Pro

Point-Counterpoint: Active Surveillance 0:09:59

Point-Counterpoint: Active Surveillance for Intermediate-Risk Prostate Cancer - Con

Point-Counterpoint: Oncotype Dx 0:17:45

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Point-Counterpoint Q&A w/ 0:16:11

Point-Counterpoint Q&A w/ Dr. Lin: Oncotype Dx Genomic Prostate Score in Active Surveillance

Point-Counterpoint Q&A w/ 0:08:07

Point-Counterpoint Q&A w/ Dr. Klein: Oncotype Dx Genomic Prostate Score in Active Surveillance

Point-Counterpoint: Will Conventional 0:11:36

Point-Counterpoint: Will Conventional Imaging Become Obsolete? – Con

Prostate Cancer Active 0:09:14

Prostate Cancer Active Surveillance in 2019

Urowebinar: MRI and 0:54:39

Urowebinar: MRI and active surveillance in prostate cancer

Guidelines Based Management 0:24:40

Guidelines Based Management of Localized and Locally Advanced RCC

Can Genomics Improve 0:24:38

Can Genomics Improve Upon Best Clinical Risk Stratification?

All Men with 0:09:39

All Men with Prostate Cancer and All Patients with Advanced Disease Should Undergo Germline Testing

There is a 0:10:04

There is a Role for Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

Point-Counterpoint: Muscle Invasive 0:14:13

Point-Counterpoint: Muscle Invasive Bladder Cancer–Trimodal Therapy Perspective

Weill Cornell Urology 0:54:38

Weill Cornell Urology - Grand Rounds: Dr. Behfar Ehdaie

Pro: The Role 0:08:53

Pro: The Role of Currently Available Biomarkers Genomics in Risk Stratification of Prostate Cancer

Debate: Surgery vs. 0:17:31

Debate: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer– Brachytherapy

New Concepts in 0:27:50

New Concepts in ADT

Industry Perspective: Cxbladder 0:30:04

Industry Perspective: Cxbladder Monitor Urine Genomics Test for Surveillance of Patients with NMIBC

The 'Who's' of 0:12:53

The 'Who's' of Genomic Markers: Who to Treat

Industry Perspective: The 0:08:43

Industry Perspective: The Oncotype DX Genomic Prostate Score Assay Test

Prostate Cancer; Evaluating 0:52:22

Prostate Cancer; Evaluating Elevated PSA; Screening Prostate Cancer; MRI Biopsy; Active Surveillance

Shared Decision Making 0:24:41

Shared Decision Making for Prostate Cancer Decisions

Universal Germline Screening 0:05:18

Universal Germline Screening in Prostate Cancer - The Argument Against

Dr. Katz on 0:02:25

Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer

Комментарии
Автор

It seems to me that the problem with this analysis is that Watchful Waiting and Active Surveillance; Favorable Intermediate and Unfavorable Intermediate groups are being conflated within the presentation. They are not are clearly defined within the studies. Conclusions are being drawn by the presenter when the studies themselves do not define groups clearing (WW, AS, FI, UI), and, therefore outcome. Specially, the CAPRA, at least within the presentation, if there was a differentiation between FI and UI. Also, this study was 2011. Wouldn’t MRI have evaluated more by 2023 that the patients could have been reclassified had they had a T3 imager. Maybe even the biopsy methods have improved. This presentation just seems to this therefore that thinking.

MM-sfrl